A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non-small-cell lung cancer who have progressed after anti-PD-1/L1 therapy.
Yuguang ZhaoXiao ChenJun YaoJianlin LongYong MaoDi WuAimin ZangJun ZhaoZiling LiuRui MengYe ChenYang LuoQun GuoLi LiJiu-Wei CuiPublished in: Cancer medicine (2024)
IBI310 3 mg/kg Q3W plus sintilimab was effective in a small number of previously treated anti-PD-1/L1-resistant NSCLC patients.